Bispep87.5 mg/5 ml

Bispep is an antidiarrheal and gastroprotective agent used for the following indications:

Established / OTC-approved uses

• Symptomatic relief of diarrhea, including travelers' diarrhea
• Relief of upset stomach, indigestion, heartburn, and nausea associated with overeating or drinking

Guideline-supported combination-therapy use

• As part of a multi-drug (quadruple) regimen with an antibiotic combination and a proton pump inhibitor or H2-blocker for eradication of Helicobacter pylori infection in patients with duodenal ulcer disease. Bispep alone does not eradicate H. pylori; it must be combined with antibiotics as directed by a physician.

Bispep is not a substitute for oral rehydration therapy in significant fluid loss, and is not intended for chronic or prolonged use without medical supervision.

Each dosage form of Bismuth Subsalicylate contains bismuth subsalicylate as the active ingredient. Common strengths marketed include:

• Chewable/regular tablets: 262 mg bismuth subsalicylate
• Extra-strength liquid: 525 mg per 15 mL
• Oral suspension (as commonly available in Bangladesh): 87.5 mg per 5 mL

Inactive ingredients vary by manufacturer and formulation (flavoring, suspending agents, preservatives).

Bispep is a bismuth compound combined with salicylate, available without prescription as an antidiarrheal, antacid, and gastrointestinal protectant. It has been used for decades for symptomatic relief of mild digestive upset and diarrhea, and as part of combination regimens for Helicobacter pylori eradication. Bispep is practically insoluble in water and is formulated as chewable tablets, caplets, or oral suspensions.

Bispep belongs to the therapeutic class of antidiarrheal and gastrointestinal protectant/adsorbent agents. Chemically it is classified as a salicylate (a bismuth salt of salicylic acid), giving it both mild antisecretory (salicylate-related) and antimicrobial/protective (bismuth-related) properties.

Bismuth Subsalicylate has a dual mechanism of action arising from its two components:

• Salicylate component: Inhibits intestinal prostaglandin synthesis, reducing intestinal inflammation and fluid/electrolyte secretion, which helps reduce stool frequency and looseness.
• Bismuth component: Exerts direct antimicrobial activity against enteric bacterial and viral pathogens (including Escherichia coli and Helicobacter pylori), binds bacterial toxins, and forms a protective coating over the gastric and intestinal mucosa, including ulcerated surfaces.

Following ingestion, bismuth subsalicylate is hydrolyzed in the gut; the salicylate portion is absorbed systemically and metabolized/excreted similarly to other salicylates, while most of the bismuth is excreted unabsorbed in the stool, with a small fraction absorbed and eliminated renally.

Bispep is for oral use only. Shake liquid suspensions well before each use. Chewable tablets should be chewed or allowed to dissolve in the mouth before swallowing; caplets/tablets may be swallowed whole with water. May be taken with or without food. Do not exceed the recommended dose or duration of use without medical advice.

Bispep has the following well-established clinically significant interactions:

• Aspirin and other salicylates: Concurrent use increases the risk of additive salicylate toxicity (salicylism); avoid combining Bispep with aspirin-containing products, especially in patients already on chronic aspirin therapy.
• Anticoagulants (e.g., warfarin): The salicylate component may enhance bleeding risk; concurrent use requires medical supervision.
• Tetracycline antibiotics: Bismuth can chelate tetracyclines and reduce their gastrointestinal absorption; doses should be separated in time if co-administered (relevant mainly when both are used together in H. pylori regimens, where spacing is already built into the prescribed schedule).
• Methotrexate and probenecid: Salicylates may reduce renal clearance of these drugs, increasing the risk of toxicity.
• Oral hypoglycemic agents: Salicylates may theoretically potentiate glucose-lowering effects; monitor blood glucose if used concurrently.

Common and expected effects of Bispep:

• Temporary, harmless darkening (grayish-black) of the tongue and/or stool — this is expected and should be distinguished from melena (blood in stool); it resolves after stopping the medicine.
• Mild constipation

Less common/serious effects (usually associated with high-dose or prolonged use):

• Tinnitus (ringing in the ears) or hearing changes — an early sign of salicylate toxicity; discontinue and seek medical advice
• Rare bismuth-related neurotoxicity (confusion, unsteady gait) with prolonged excessive dosing
• Hypersensitivity reactions (rash, itching)

Pregnancy: Data on the safety of Bispep in pregnancy are limited. Because Bispep contains a salicylate, and salicylates in general are associated with potential risks in pregnancy (particularly in the third trimester), Bispep should be used in pregnancy only if clearly needed and only after consulting a physician, who will weigh the potential benefit against potential risk to the fetus.

Lactation: It is not well established whether the salicylate component passes into breast milk in clinically significant amounts. Breastfeeding mothers should use Bispep only if clearly needed and after consulting a physician, particularly given the theoretical association between salicylates and Reye's syndrome in children.

• Do not use Bispep for more than 2 days for diarrhea; discontinue and consult a physician if diarrhea persists beyond 2 days, is accompanied by high fever, or if blood is present in the stool.
• Avoid concurrent use with other salicylate-containing products (including aspirin) because of additive salicylate toxicity risk (see Interactions).
• Use with caution in patients on anticoagulant therapy due to potential enhanced bleeding risk (see Interactions).
• Use with caution in patients with renal impairment; prolonged or high-dose use may lead to bismuth accumulation and toxicity.
• Bispep causes temporary, harmless darkening of the tongue and stool; this should not be mistaken for gastrointestinal bleeding (see Side Effects).
• Bispep can interfere with certain diagnostic tests (e.g., it is radio-opaque and may obscure findings on abdominal X-rays); inform your physician if you are scheduled for such tests.
• Stop use and seek medical attention if ringing in the ears, hearing loss, or signs of an allergic reaction occur.

Overdose of Bispep can lead to salicylate toxicity, with symptoms such as ringing in the ears (tinnitus), nausea, vomiting, rapid or deep breathing, confusion, and, in severe cases, seizures or metabolic disturbances. Chronic excessive dosing may rarely cause bismuth-related neurotoxicity. In case of suspected overdose, seek immediate medical attention or contact a poison control center right away; do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Bispep is not recommended for self-medication (OTC use) in children under 12 years without physician guidance, primarily due to the association of the salicylate component with Reye's syndrome when used in children/teenagers with viral illnesses (see Contraindications). Where a physician directs use of an oral suspension in younger children (e.g., ages 5–14, as available in some markets), dosing is weight/age-adjusted and should follow the prescriber's instructions precisely. Safety and efficacy in infants and very young children have not been established for self-administered OTC use.

Elderly

Use with caution in elderly patients, who may have age-related decline in renal function affecting bismuth and salicylate elimination; monitor for early signs of salicylate toxicity.

Renal impairment

Use with caution; avoid prolonged or high-dose use due to risk of bismuth accumulation and salicylate toxicity in reduced renal clearance.

Hepatic impairment

No specific dose adjustment is established; use with general caution and medical supervision.

For OTC self-treatment of diarrhea or upset stomach, Bispep should not be used for more than 2 consecutive days without consulting a physician. When used as part of a prescribed multi-drug regimen for H. pylori eradication, treatment duration is typically 10–14 days as directed by the prescribing physician; the full prescribed course should be completed as directed.

Bismuth Subsalicylate is classified under: Antidiarrheal agents; Gastrointestinal protectants/adsorbents; Salicylates (bismuth salt of salicylic acid).

Bismuth Subsalicylate acts through a combined salicylate anti-secretory/anti-inflammatory effect on the intestinal mucosa (reducing prostaglandin-mediated fluid secretion) and a bismuth-mediated antimicrobial and mucosal-protective (coating/adsorbent) effect against enteric pathogens and their toxins.

Bispep is not generally recommended for OTC self-use in children under 12 years of age because of the theoretical association between its salicylate component and Reye's syndrome, particularly during or after chickenpox or influenza-like illness (see Contraindications). Physician-directed use in younger children with an appropriately weight/age-adjusted oral suspension is described under Use in Special Populations, but should only occur under medical supervision. Safety and efficacy for unsupervised OTC use below age 12 have not been established.